[{"data":1,"prerenderedAt":443},["ShallowReactive",2],{"tool-healthcare-pharmcube":3,"footer-total":416,"related-healthcare-pharmcube":417},{"id":4,"title":5,"author":6,"bestFor":7,"body":8,"category":374,"cons":375,"cover":381,"date":382,"description":383,"draft":384,"extension":385,"meta":386,"navigation":387,"notFor":388,"path":389,"pricing":390,"pros":394,"region":400,"score":401,"scoreBreakdown":402,"seo":408,"stem":409,"tags":410,"toolName":217,"updated":382,"url":414,"vendor":217,"__hash__":415},"tools\u002Ftools\u002Fhealthcare\u002Fpharmcube.md","医药魔方 评测","元析评测","创新药企的 BD、战略与临床开发团队,以及看医药一级市场交易的投资机构",{"type":9,"value":10,"toc":346},"minimark",[11,15,23,26,29,51,54,59,62,65,69,72,75,79,82,85,88,92,95,99,102,106,109,113,116,120,123,126,200,203,206,296,302,306,310,313,317,320,324,327,331,334,337,340],[12,13,14],"h2",{"id":14},"结论先行",[16,17,18,22],"p",{},[19,20,21],"strong",{},"推荐,总分 8.2;官网不标价,先申请试用、再按产品线议价,没有公开价目表。"," 医药魔方把医药数据拆成 12 条产品线:NextPharma 看全球新药管线,NextPat 看专利,NextDevice 看器械,NextBioSeq 看生物序列,PharmaGO 查药品基础信息,TrialiCube 收临床试验,InvestGO 管投融资与 BD 交易,PharmaBI 四条线分别对应医院渠道、零售渠道、患者潜力与市场销售。",[16,24,25],{},"这套结构对创新药企与投资机构顺手:一个标的从靶点、临床阶段、专利到期到交易对价,能在几条线里拼出来,不用跨三个平台。对只想查批文、看零售销售额的团队就不划算,那些需求用更便宜的库能满足。官网只给\"申请试用\"入口和销售电话,没有任何价格。",[12,27,28],{"id":28},"这篇评测基于什么数据",[30,31,32,36,39,42,45,48],"ul",{},[33,34,35],"li",{},"官网首页与产品导航(2026-11 核对):12 条数据产品的名称与定位说明,含 NextPharma、TrialiCube、InvestGO、PharmaBI 四线",[33,37,38],{},"官网公开的客户规模:1000 家以上国内外药企与投资机构客户,媒体侧 80 万行业读者、300 多家行业客户",[33,40,41],{},"咨询业务说明:六类项目覆盖竞争格局与开发规划、临床评价与推广策略、市场潜力评估与估值、管线筛选、定价与准入、行业与企业调研",[33,43,44],{},"免费资源区 ByDrug:提供部分报告与器械、药品数据查询",[33,46,47],{},"定价:官网只有试用申请与销售电话,未公布价目",[33,49,50],{},"实测说明:未购买正式账号做全库验证,以下判断来自官网产品说明、公开报告与试用入口,未做统一环境实测",[12,52,53],{"id":53},"核心功能",[55,56,58],"h3",{"id":57},"nextpharma全球管线的横向对比","NextPharma:全球管线的横向对比",[16,60,61],{},"NextPharma 是整套产品的入口。它以药品为对象,把靶点、作用机制、适应症、研发阶段、原研与跟随企业、专利到期时间放在同一页。做同靶点竞争分析,先筛出某靶点全部在研项目,再按临床阶段排序,能一眼看出谁是第一梯队、谁刚进临床一期。",[16,63,64],{},"它对\"全球同步\"这件事处理得比较认真:同一品种在中美欧的申报与临床进度分列,不会把国内的进度当全球进度。做 license-out 材料时,这个区分很关键,买方第一句就问全球权益与区域进度。",[55,66,68],{"id":67},"trialicube-与-investgo把交易和试验连起来","TrialiCube 与 InvestGO:把交易和试验连起来",[16,70,71],{},"TrialiCube 按临床试验方案组织数据,可按分期、样本量、申办方、主要终点筛选,还能看出某个适应症近三年试验数量的变化。找竞品试验设计参考,比自己翻注册平台快。",[16,73,74],{},"InvestGO 收的是投融资与 BD 事件:融资金额、投资方、交易对价、首付款与里程碑结构。它和管线数据打通,查一个标的能同时看到资产进度和交易价格,做估值参考时这条链比新闻稿可靠。需要注意的是,未披露金额的交易很多,数据库里会留空,别把空值当零。",[55,76,78],{"id":77},"pharmabi-与咨询中文市场那一半","PharmaBI 与咨询:中文市场那一半",[16,80,81],{},"PharmaBI 分四条线:IPM 对应医院渠道竞品监测,HCM 对应实体零售渠道,RCM 是医院患者潜力,HPI 是市场销售数据。国内市场的份额、渠道分布、患者流向要靠这四条线,它们和全球管线数据不在同一个界面。",[16,83,84],{},"咨询是独立业务,六类项目从竞争格局规划到定价与准入政策都接。数据客户想加定制研究,要另走销售与项目流程,交付周期按项目算。",[12,86,87],{"id":87},"评分明细",[55,89,91],{"id":90},"功能完整度8810","功能完整度:8.8\u002F10",[16,93,94],{},"从靶点发现到市场销售,链条上每一环都有对应产品,全球与中国两侧都有覆盖。扣分在真实世界数据与医保准入明细,这两块相对薄。",[55,96,98],{"id":97},"易用性7810","易用性:7.8\u002F10",[16,100,101],{},"单条产品的检索做得清楚,筛选维度贴合 BD 的工作语言。扣分在产品线之间交互不一致,同一家公司要在不同界面重复登录、重复筛选,学习成本按线累加。",[55,103,105],{"id":104},"数据质量8910","数据质量:8.9\u002F10",[16,107,108],{},"最强项。管线字段的来源标注清楚,临床阶段与试验编号能对回注册平台,交易事件有时间与对价结构。扣分在部分海外中小企业的管线更新有延迟,以及未披露金额的字段留空较多。",[55,110,112],{"id":111},"性价比7210","性价比:7.2\u002F10",[16,114,115],{},"单条线对专业用户不算贵,买齐就贵了。12 条线全买的团队很少,常见组合是 NextPharma 加 TrialiCube,再用 PharmaBI 补国内。续约折扣没有公开规则,预算要按上限留。",[55,117,119],{"id":118},"客户支持8010","客户支持:8.0\u002F10",[16,121,122],{},"有试用、有客户成功对接,媒体与报告输出稳定,行业会议常年办,能当面问产品路线。扣分在售后按产品线分团队,跨线问题要转手。",[12,124,125],{"id":125},"定价说明",[127,128,129,145],"table",{},[130,131,132],"thead",{},[133,134,135,139,142],"tr",{},[136,137,138],"th",{},"产品线",[136,140,141],{},"价格",[136,143,144],{},"说明",[146,147,148,160,170,180,190],"tbody",{},[133,149,150,154,157],{},[151,152,153],"td",{},"NextPharma 全球新药",[151,155,156],{},"未公开",[151,158,159],{},"按账号与模块议价,官网仅提供试用申请",[133,161,162,165,167],{},[151,163,164],{},"TrialiCube 临床试验",[151,166,156],{},[151,168,169],{},"可单独购买,常与 NextPharma 打包",[133,171,172,175,177],{},[151,173,174],{},"InvestGO 投融资",[151,176,156],{},[151,178,179],{},"按席位计价,投资机构常用",[133,181,182,185,187],{},[151,183,184],{},"PharmaBI 四线",[151,186,156],{},[151,188,189],{},"医院、零售、患者潜力、市场销售分开授权",[133,191,192,195,197],{},[151,193,194],{},"咨询与定制研究",[151,196,156],{},[151,198,199],{},"按项目报价,周期以月计",[16,201,202],{},"2026-11 核对官网,产品页只写定位与功能,价格一律走销售。谈价前先明确三件事:需要的产品线、账号数、是否要数据接口。销售习惯推打包,但 BD 团队高频用的通常只有两三条线,按需买更省。合同要写清历史数据回溯年限与导出限制,这两项在续约时最容易被动。",[12,204,205],{"id":205},"和竞品对比",[127,207,208,224],{},[130,209,210],{},[133,211,212,215,218,221],{},[136,213,214],{},"维度",[136,216,217],{},"医药魔方",[136,219,220],{},"药智网",[136,222,223],{},"米内网",[146,225,226,240,254,268,282],{},[133,227,228,231,234,237],{},[151,229,230],{},"主打",[151,232,233],{},"全球新药情报与 BD 交易",[151,235,236],{},"药品研发与注册情报",[151,238,239],{},"终端销售与市场格局",[133,241,242,245,248,251],{},[151,243,244],{},"起步价",[151,246,247],{},"未公开,按模块议价",[151,249,250],{},"未公开,分专业版与企业版",[151,252,253],{},"未公开,按年议价",[133,255,256,259,262,265],{},[151,257,258],{},"强项",[151,260,261],{},"管线、临床试验、投融资、专利",[151,263,264],{},"受理号级注册数据、一致性评价",[151,266,267],{},"医院与药店终端销售额",[133,269,270,273,276,279],{},[151,271,272],{},"中文市场",[151,274,275],{},"PharmaBI 四线单买",[151,277,278],{},"销售数据线较浅",[151,280,281],{},"核心能力",[133,283,284,287,290,293],{},[151,285,286],{},"短板",[151,288,289],{},"价格高、产品线割裂",[151,291,292],{},"账号分散",[151,294,295],{},"研发字段浅",[16,297,298,301],{},[19,299,300],{},"怎么选",":做创新药立项、找 BD 标的、给投资决策做支撑,选医药魔方;跟注册申报与一致性评价打交道,选药智网;要算品类在院内院外的销售额,选米内网。三家都不标价,同一年度预算下建议同时要方案,把\"产品线、账号、回溯年限、接口\"四项列成表再比。",[12,303,305],{"id":304},"faq","FAQ",[55,307,309],{"id":308},"q-医药魔方有个人能买得起的版本吗","Q: 医药魔方有个人能买得起的版本吗?",[16,311,312],{},"A: 没有公开的轻量版。官网只提供试用申请,正式授权按产品线与账号数计价,面向企业与机构。个人研究者可以先用免费资源区 ByDrug 的报告与查询,覆盖公开信息够用,深度管线字段仍需机构授权。",[55,314,316],{"id":315},"q-nextpharma-和-pharmago-有什么区别","Q: NextPharma 和 PharmaGO 有什么区别?",[16,318,319],{},"A: NextPharma 盯在研与全球新药竞争,字段偏研发阶段、靶点、临床试验;PharmaGO 查已上市药品的基础信息,偏批文、说明书、适应症。做立项看前者,做产品资料核对看后者。两者有交叉但不重合。",[55,321,323],{"id":322},"q-数据能导出做内部模型吗","Q: 数据能导出做内部模型吗?",[16,325,326],{},"A: 能导出,额度和字段范围按合同走,部分产品线支持接口。批量导出通常要单独授权,价格另算。导出数据一般限定企业内部使用,对外发布要注明来源并取得许可,这条在合同里有明确条款。",[55,328,330],{"id":329},"q-中国市场的销售数据准不准","Q: 中国市场的销售数据准不准?",[16,332,333],{},"A: PharmaBI 的四条线是独立推算模型,和专做医院、药店监测的厂商口径不同,同一品种的份额排名可能不一致。看趋势用它没问题,做对外披露的绝对值建议交叉验证,并在材料里写明数据来源与口径。",[12,335,336],{"id":336},"评测方法说明",[16,338,339],{},"元析评测围绕功能完整度、易用性、数据质量、性价比、客户支持五个维度打分,每项满分 10 分,加权折算总分。医药魔方的 12 条产品线清单、客户规模与试用入口核对于 2026-11,所有价格因官网未公开而留空,实际授权以销售合同为准。我们没有购买正式账号,界面与导出体验的描述基于试用入口与公开产品文档。",[16,341,342,345],{},[19,343,344],{},"最后更新",":2026-11-16",{"title":347,"searchDepth":348,"depth":348,"links":349},"",2,[350,351,352,358,365,366,367,373],{"id":14,"depth":348,"text":14},{"id":28,"depth":348,"text":28},{"id":53,"depth":348,"text":53,"children":353},[354,356,357],{"id":57,"depth":355,"text":58},3,{"id":67,"depth":355,"text":68},{"id":77,"depth":355,"text":78},{"id":87,"depth":348,"text":87,"children":359},[360,361,362,363,364],{"id":90,"depth":355,"text":91},{"id":97,"depth":355,"text":98},{"id":104,"depth":355,"text":105},{"id":111,"depth":355,"text":112},{"id":118,"depth":355,"text":119},{"id":125,"depth":348,"text":125},{"id":205,"depth":348,"text":205},{"id":304,"depth":348,"text":305,"children":368},[369,370,371,372],{"id":308,"depth":355,"text":309},{"id":315,"depth":355,"text":316},{"id":322,"depth":355,"text":323},{"id":329,"depth":355,"text":330},{"id":336,"depth":348,"text":336},"healthcare",[376,377,378,379,380],"12 条产品线拆开卖,想覆盖从立项到上市全流程要买好几条,总价不低且不透明","单条线的界面与交互不一致,学习成本按线累加,新同事要分别带教","中文终端销售数据只在 PharmaBI 里,覆盖深度不及专做医院与药店监测的老牌厂商","官方定价与折扣都走销售,续约涨幅没有公开规则,预算不好提前排","媒体与咨询是两块独立业务,数据客户想加定制研究要另走一套流程",null,"2026-11-16","医药魔方评测:12 条数据产品线覆盖管线、临床试验与投融资,官网不标价、要申请试用后议价;全球新药字段扎实、中英双语,适合创新药企 BD 与投资机构;中文终端销售数据靠 PharmaBI 单买。",false,"md",{},true,"只做仿制药批文查询、或只关心院内零售销售额的传统药企市场部","\u002Ftools\u002Fhealthcare\u002Fpharmcube",{"free":384,"startingPrice":347,"currency":391,"billingPeriod":392,"notes":393},"CNY","年","数据产品共 12 条线,按产品模块与账号数议价;官网只提供“申请试用”入口与销售电话,未公布价目表。ByDrug 免费资源区可下载部分报告。官网未公开报价,需联系销售。价格于 2026-11 核对官网。",[395,396,397,398,399],"NextPharma 覆盖全球新药管线,字段含靶点、适应症、临床阶段与竞争格局,一个品种的全球进度能在一页看完","TrialiCube 按临床试验方案组织数据,可按分期、样本量、申办方、终点指标筛选,做竞品试验设计参考很快","InvestGO 打通投融资事件与管线,查一笔 BD 交易的对价与标的资产不用再翻新闻","PharmaBI 四条线分别对应医院渠道、零售渠道、患者潜力与市场销售,能补上终端侧的空缺","中英双语界面,海外授权与跨境 BD 场景里可直接把页面截图给对方看","cn",8.2,{"features":403,"ease":404,"data":405,"price":406,"support":407},8.8,7.8,8.9,7.2,8,{"title":5,"description":383},"tools\u002Fhealthcare\u002Fpharmcube",[411,412,413,217],"医疗健康","医药数据","新药情报","https:\u002F\u002Fwww.pharmcube.com","0_gZVg7zF6WjYiIgf366STHdgzBV0_Y6MscaOaLfHrE",1016,[418,427,435],{"path":419,"toolName":420,"description":421,"score":422,"pricing":423,"vendor":425,"date":426,"category":374},"\u002Ftools\u002Fhealthcare\u002Fdxy","丁香医生","丁香医生是丁香园旗下院外健康平台,集团官网写明注册医师 450 万+,App 首次问诊 9.9 元起,科普内容有医生审稿。它适合药企做患者教育、个人问小病,不适合当医院信息系统用,也不做医保结算,问诊只是轻咨询。",8.6,{"free":387,"startingPrice":347,"currency":391,"billingPeriod":392,"notes":424},"C 端免费使用,问诊按次付费,App Store 官方文案写明首次问诊 9.9 元起,复诊单价由接诊医生设定。药企内容合作、医院科普项目等机构业务官网未公开标准报价,需联系销售。价格核对时间 2026-11。","丁香园","2026-11-04",{"path":428,"toolName":429,"description":430,"score":431,"pricing":432,"vendor":429,"date":434,"category":374},"\u002Ftools\u002Fhealthcare\u002Falihealth","阿里健康","阿里健康是阿里系医药与医疗平台,官网披露天猫健康 4.83 万商家、大药房 123 万 SKU、码上放心服务 7100 家流通企业。强项在商家规模与药品追溯合规,适合药企做渠道,不适合想买独立 HIS 的医院,云医院由合作方实施。",8.5,{"free":384,"startingPrice":347,"currency":391,"billingPeriod":392,"notes":433},"C 端购药与问诊按件、按次付费,无独立订阅套餐。天猫健康入驻涉及保证金与技术年费,码上放心按追溯码用量或年度服务计费,官网均未公开标准报价,需联系销售。价格核对时间 2026-11。","2026-10-22",{"path":436,"toolName":437,"description":438,"score":439,"pricing":440,"vendor":437,"date":442,"category":374},"\u002Ftools\u002Fhealthcare\u002Fhaodf","好大夫在线","好大夫在线收录 10450 家医院、931617 位大夫,App 写明 28 万医生入驻、服务 8900 万患者。它是医生个人品牌的入口,问诊价格由医生定,适合副主任以上医生和找专病专家的患者。不适合急诊,入驻免费但抽成不公开,签约前要多看同城案例。",8.3,{"free":387,"startingPrice":347,"currency":391,"billingPeriod":392,"notes":441},"患者浏览医生主页、看评价免费,图文、电话、视频问诊按医生自报价付费,私人医生与优选会员为付费服务。医生入驻不收费。平台抽成比例与机构合作报价官网未公开标准报价,需联系销售。价格核对时间 2026-11。","2026-10-29",1794788232781]